>>Signaling Pathways>> PROTAC>> Ligand for E3 Ligase>>(S,R,S)-AHPC

(S,R,S)-AHPC (Synonyms: VH032-NH2; VHL ligand 1)

Catalog No.GC62283

(S,R,S)-AHPC(VH032-NH2)는 von Hippel-Lindau(VHL) 단백질 모집에 사용되는 VH032 기반 VHL 리간드입니다. (S,R,S)-AHPC는 링커에 의해 단백질에 대한 리간드(예: BCR-ABL1)에 연결되어 PROTAC(예: GMB-475)를 형성할 수 있습니다. GMB-475는 Ba/F3 세포에서 1.11μM의 IC50으로 BCR-ABL1의 분해를 유도합니다.

Products are for research use only. Not for human use. We do not sell to patients.

(S,R,S)-AHPC Chemical Structure

Cas No.: 1448297-52-6

Size 가격 재고 수량
50 mg
US$230.00
재고 있음
100 mg
US$360.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com


고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

(S,R,S)-AHPC (VH032-NH2) is the VH032-based VHL ligand used in the recruitment of the von Hippel-Lindau (VHL) protein. (S,R,S)-AHPC can be connected to the ligand for protein (e.g., BCR-ABL1) by a linker to form PROTACs (e.g., GMB-475). GMB-475 induces the degradation of BCR-ABL1 with an IC50 of 1.11 μM in Ba/F3 cells[1].

The VHL protein is a substrate recognition subunit of two ubiquitously expressed and biologically important Cullin RING E3 ubiquitin ligase complexes. VHL is one of the most popular E3 ligases being recruited by bifunctional Proteolysis-targeting chimeras (PROTACs) to induce ubiquitination and subsequent proteasomal degradation of a target protein.

[1]. Burslem GM, et al. Targeting BCR-ABL1 in Chronic Myeloid Leukemia by PROTAC-mediated Targeted Protein Degradation. Cancer Res. 2019 Jul 16. pii: canres.1236.2019.

리뷰

Review for (S,R,S)-AHPC

Average Rating: 5 ★★★★★ (Based on Reviews and 24 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for (S,R,S)-AHPC

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.